![]() HER2-enriched tumors tend to be :Ībout 10-15 percent of breast cancers are HER2-enriched subtype. The molecular subtype HER2-enriched is not the same as HER2-positive and is not used to guide treatment.Īlthough most HER2-enriched tumors are HER2-positive (and named for this reason), many are HER2-negative. Learn about clinical trials for people with basal-like/triple negative breast cancers. Learn more about triple negative breast cancer, including prognosis and treatment. However, they can be treated effectively, and with new treatments for TNBC, prognosis is improving. Prognosisīasal-like/triple negative tumors are often aggressive and have a poorer prognosis (lower chance of survival) compared to the ER-positive subtypes (luminal A and luminal B tumors). Learn more about BRCA1 inherited gene mutations. Triple negative tumors may also be more common among Hispanic women compared to non-Hispanic white women. Black, non-Hispanic Black and African American women ( more on race/ethnicity and subtypes of breast cancer).People with a BRCA1 inherited gene mutation (if you’re diagnosed with TNBC, the National Comprehensive Cancer Network recommends you get genetic testing).These tumors tend to occur more often in : Most triple negative tumors are basal-like (see figure below).Ībout 15-20 percent of breast cancers are basal-like/triple negative. Progesterone receptor-negative (PR-negative).Estrogen receptor-negative (ER-negative). ![]() Basal-like/triple negativeīasal-like tumors have cells that look similar to those of the outer (basal) cells surrounding the mammary ducts. Women with luminal B tumors tend to have fairly high survival rates, although not as high as those with luminal A tumors. Ĭompared to luminal A tumors, luminal B tumors tend to have factors that lead to a poorer prognosis including :Ībout 15-20 percent of breast cancers are luminal B tumors. Women with luminal B tumors are often diagnosed at a younger age than those with luminal A tumors. They may be HER2-negative or HER2-positive. Luminal tumor cells look like the cells of breast cancers that start in the inner (luminal) lining the mammary ducts. Of the 4 main molecular subtypes, luminal A tumors tend to have the best prognosis (chance of survival), with fairly high survival rates and fairly low breast cancer recurrence rates.
0 Comments
Leave a Reply. |